Fruitless search for patients stymies prostate cancer trial

1 November 2022
research_biotech_lab_computer_results_big

Trouble recruiting patients has thrown a wrench in the works of efforts to develop a novel prostate cancer treatment, EPI-7386.

Canadian prostate cancer specialist ESSA Pharma (Nasdaq:  EPIX) has been working with Johnson & Johnson (NYSE: JNJ) to test the novel drug in combination with Erleada (apalutamide) or Zytiga (abiraterone acetate), plus prednisone.

ESSA, which retains all rights to EPI-7386 globally, believes the therapy could be used as a way to delay resistance to existing drugs used to treat prostate cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical